Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Muang, Chiang Mai 50200, Thailand; Musculoskeletal Science and Translational Research Center (MSTR), Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Musculoskeletal Science and Translational Research Center (MSTR), Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Crit Rev Oncol Hematol. 2021 Oct;166:103455. doi: 10.1016/j.critrevonc.2021.103455. Epub 2021 Aug 28.
Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising biomarker in the advancement of cancer management, including early diagnosis, screening, prognosis, identification of actionable targets, and serial tumor monitoring. The specific size pattern of DNA fragments derived from cancer cells is observed to differ from that of cfDNA fragments shed by non-cancer cells. Research into the physiological and biological properties of cfDNA reveals the molecular signature carried by each cfDNA fragments, which can reflect their tissue origins, as well as the mutational profiles with significant genetic alterations. Understanding the fragmentation and size distribution of cfDNA might be a valuable hotspot in liquid biopsy research, with the potential to drive innovation in oncology.
肿瘤特异性、循环游离 DNA（cfDNA）在液体活检检测中是癌症管理进展中的一种有前途的新型生物标志物，包括早期诊断、筛查、预后、可操作靶点的识别和连续肿瘤监测。源自癌细胞的 DNA 片段的特定大小模式观察到与非癌细胞释放的 cfDNA 片段的不同。对 cfDNA 的生理和生物学特性的研究揭示了每个 cfDNA 片段所携带的分子特征，这些特征可以反映它们的组织起源，以及具有显著遗传改变的突变特征。了解 cfDNA 的碎片化和大小分布可能是液体活检研究中的一个有价值的热点，有可能推动肿瘤学的创新。
